Connection

Helmut Albrecht to Anti-Retroviral Agents

This is a "connection" page, showing publications Helmut Albrecht has written about Anti-Retroviral Agents.
Connection Strength

0.845
  1. HIV community viral load trends in South Carolina. Int J STD AIDS. 2017 03; 28(3):265-276.
    View in: PubMed
    Score: 0.522
  2. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372.
    View in: PubMed
    Score: 0.159
  3. Rare case of rilpivirine-induced severe allergic hepatitis. J Antimicrob Chemother. 2013 Feb; 68(2):484-6.
    View in: PubMed
    Score: 0.101
  4. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina. South Med J. 2018 06; 111(6):355-358.
    View in: PubMed
    Score: 0.037
  5. Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011. Metab Syndr Relat Disord. 2013 Dec; 11(6):417-26.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.